SEC Forn F	n 4 -ORM 4	4 UI	NITEI	D STAT	TES S	SEC	URITIE	S AN	DE	XCHAN	IGE C	OM	MISSIO	N		
					Washington, D.C. 20549									0	OMB APPR	OVAL
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).				Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									RSHIP	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
1. Name and Address of Reporting Person* Bozic Carmen (First) (First)					VE	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below)			Owner (specify
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED					3. Date of Earliest Transaction (Month/Day/Year) 02/01/2023									EVP a	nd CMO	
50 NORTHERN AVENUE (Street) BOSTON MA 02210					4. If A	I. If Amendment, Date of			f Original Filed (Month/I				ne) X Form	n filed by On n filed by Mo	p Filing (Check e Reporting Pe rre than One Re	rson
(City)	(Sta	ate) (Z	Zip)													
		Table	I - No	n-Deriva	tive S	ecui	rities Acq	uired,	Dis	posed of	or Be	nefic	ially Own	ed		
Date					n/Day/Year) if a		Deemed ution Date, / th/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquire Disposed Of (D) (Inst 5)		d (A) oi r. 3, 4 a	nd Secur Benef Owne	icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
								Code	v	Amount	(A) or (D)	Price		ted action(s) 3 and 4)		(Instr. 4)
Common Stock				02/01/2023				Α		10,324(1)	Α	\$ <mark>0</mark> .	00 5	9,836	D	
Common Stock			02/01/2023				A		10,262(2)	A	\$ <mark>0</mark> .	00 7	0,098	D		
Common Stock 0				02/01/2	2023			Α		7,866 ⁽³⁾	A	\$ <mark>0</mark> .	00 7	7,964	D	
		Tal					ties Acqu varrants,							d		
Derivative Security (Instr. 3)	tive Conversion Date Execution ity or Exercise (Month/Day/Year) if any		ion Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)			Amount of De Securities Se		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y Direct (D or Indirec (I) (Instr.	Beneficial Ownership t (Instr. 4)	

Explanation of Responses:

1. Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023.

(D)

(A)

Date Exercisable Expiration

Date

2. Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023.

3. Restricted stock unit award that vests in installments beginning on 02/10/2024.

Remarks:

<u>/s/ Christiana Stevenson,</u> <u>Attorney-in-Fact</u>

or Numbei of

Shares

Title

** Signature of Reporting Person Date

02/03/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code V

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.